K(x)WO Is a Novel Ferroelectric Nanomaterial for Application as a Room Temperature Acetone Sensor

por Johnson, Michael E., Zhang, Qifeng, Wang, Danling
Publicado 2020

Development of specific nucleic acid probes for the differentiation of porcine rotavirus serotypes

por Johnson, Michael E., Paul, Prem S., Gorziglia, Mario, Rosenbusch, Ricardo
Publicado 1990

Mapping the energy landscape of PROTAC-mediated protein-protein interactions

por Villegas, José A., Vaid, Tasneem M., Johnson, Michael E., Moore, Terry W.
Publicado 2023

Reducing agents affect inhibitory activities of compounds: Results from multiple drug targets

por Lee, Hyun, Torres, Jaime, Truong, Lena, Chaudhuri, Rima, Mittal, Anuradha, Johnson, Michael E.
Publicado 2012

Biomarkers of Mucinous Tumors of the Ovary

por Samimi, Goli, Ozbun, Laurent, Johnson, Michael E., Mok, Samuel C., Birrer, Michael J.
Publicado 2007

Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy

por Ghosh, Arun K., Xi, Kai, Johnson, Michael E., Baker, Susan C., Mesecar, Andrew D.
Publicado 2006

Comparison of SARS and NL63 Papain-Like Protease Binding Sites and Binding Site Dynamics: Inhibitor Design Implications

por Chaudhuri, Rima, Tang, Sishi, Zhao, Guijun, Lu, Hui, Case, David A., Johnson, Michael E.
Publicado 2011

Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings

por Lee, Hyun, Mittal, Anuradha, Patel, Kavankumar, Gatuz, Joseph L., Truong, Lena, Torres, Jaime, Mulhearn, Debbie C., Johnson, Michael E.
Publicado 2014

Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling

por Lee, Hyun, Ren, Jinhong, Pesavento, Russell P., Ojeda, Isabel, Rice, Amy J., Lv, Haining, Kwon, Youngjin, Johnson, Michael E.
Publicado 2019

Synergistic Inhibitor Binding to the Papain‐Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications

por Lee, Hyun, Cao, Shuyi, Hevener, Kirk E., Truong, Lena, Gatuz, Joseph L., Patel, Kavankumar, Ghosh, Arun K., Johnson, Michael E.
Publicado 2013

High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis

por Arron, Sarah T., Dimon, Michelle T., Li, Zhenghui, Johnson, Michael E., Wood, Tammara, Feeney, Luzviminda, Angeles, Jorge Gil, Lafyatis, Robert, Whitfield, Michael L.
Publicado 2014

Identification of Small Molecule Inhibitors against Staphylococcus aureus Dihydroorotase via HTS

por Rice, Amy J., Pesavento, Russell P., Ren, Jinhong, Youn, Isoo, Kwon, Youngjin, Ellepola, Kassapa, Che, Chun-Tao, Johnson, Michael E., Lee, Hyun
Publicado 2021

Synergistic Inhibition Guided Fragment-Linking Strategy and Quantitative Structure–Property Relationship Modeling To Design Inhalable Therapeutics for Asthma Targeting CSF1R

por Vaid, Tasneem M., Demissie, Robel, Kwon, Youngjin, Tran, Thao, Moon, Hyung-Geun, Villegas, José A., Park, Gye Young, Johnson, Michael E., Lee, Hyun
Publicado 2023

Indole trimers with antibacterial activity against Gram-positive organisms produced using combinatorial biocatalysis

por McClay, Kevin, Mehboob, Shahila, Yu, Jerry, Santarsiero, Bernard D, Deng, Jiangping, Cook, James L, Jeong, Hyunyoung, Johnson, Michael E, Steffan, Robert J
Publicado 2015

Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent Cohorts

por Johnson, Michael E., Mahoney, J. Matthew, Taroni, Jaclyn, Sargent, Jennifer L., Marmarelis, Eleni, Wu, Ming-Ru, Varga, John, Hinchcliff, Monique E., Whitfield, Michael L.
Publicado 2015

Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors

por Ghosh, Arun K., Xi, Kai, Grum-Tokars, Valerie, Xu, Xiaoming, Ratia, Kiira, Fu, Wentao, Houser, Katherine V., Baker, Susan C., Johnson, Michael E., Mesecar, Andrew D.
Publicado 2007

Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors

por Ghosh, Arun K., Gong, Gangli, Grum-Tokars, Valerie, Mulhearn, Debbie C., Baker, Susan C., Coughlin, Melissa, Prabhakar, Bellur S., Sleeman, Katrina, Johnson, Michael E., Mesecar, Andrew D.
Publicado 2008

High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes

por Lee, Hyun, Zhu, Tian, Patel, Kavankumar, Zhang, Yan-Yan, Truong, Lena, Hevener, Kirk E., Gatuz, Joseph L., Subramanya, Gitanjali, Jeong, Hyun-Young, Uprichard, Susan L., Johnson, Michael E.
Publicado 2013

Inhibitor Recognition Specificity of MERS-CoV Papain-like Protease May Differ from That of SARS-CoV

por Lee, Hyun, Lei, Hao, Santarsiero, Bernard D., Gatuz, Joseph L., Cao, Shuyi, Rice, Amy J., Patel, Kavankumar, Szypulinski, Michael Z., Ojeda, Isabel, Ghosh, Arun K., Johnson, Michael E.
Publicado 2015

Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin

por Johnson, Michael E., Franks, Jennifer M., Cai, Guoshuai, Mehta, Bhaven K., Wood, Tammara A., Archambault, Kimberly, Pioli, Patricia A., Simms, Robert W., Orzechowski, Nicole, Arron, Sarah, Whitfield, Michael L.
Publicado 2019